Recent advances in development of GPR40 modulators (FFA1/FFAR1): An emerging target for type 2 diabetes

Mini-Reviews in Medicinal Chemistry

Volumn 17, Issue 11, 2017, Pages 947-958

  Sharma, Nutan ^a   Bhagat, Sunita ^a   Chundawat, Tejpal Singh ^b  

^a UNIVERSITY OF DELHI   (India)

^b THE NORTHCAP UNIVERSITY   (India)

Author keywords

Agonists; Antagonists; FFA1; FFAR1; GPR40; Insulin; Type 2 diabetes

Indexed keywords

G PROTEIN COUPLED RECEPTOR 40; ANTIDIABETIC AGENT; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR;

EXOCYTOSIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERLIPIDEMIA; INSULIN RELEASE; LIPOTOXICITY; LUCIFERASE ASSAY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; METABOLISM;

DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85025139662     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557517666170120152917     Document Type: Review

References (99)

1. [1] Saltiel, A.R.; Kahn, R.C. Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001, 414, 799-806.
2. [2] Ikenoue, T.; Okazaki, K.; Fujitani, S.; Tsuchiya, Y.; Akiyoshi, M.; Maki, T.; Kondo, N. Effect of a new hypoglycemic agent, A-4166 [(−)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenblamide. Biol. Pharm. Bull., 1997, 20, 354-359.
3. [3] Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 2004, 64, 1339-1358.
4. [4] Asplund, K.; Wiholm, B.E.; Lithner, F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia, 1983, 24, 412-417.
5. [5] Ferner, R.E.; Neil, H.A. Sulphonylureas and hypoglycaemia. Br.Med. J. (Clin. Res. Ed.), 1988, 296, 949-950.
6. [6] Maedler, K.; Carr, R. D.; Bosco, D.; Zuellig, R. A.; Berney, T.; Donath, M. Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab., 2005, 90, 501-506.
7. [7] Del Guerra, S.; Marselli, L.; Lupi, R.; Boggi, U.; Mosca, F.; Benzi, L.; Del Prato, S.; Marchetti, P. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J. Diabetes Complicat., 2005, 19, 60-64.
8. [8] Drucker, D.J.; Nauck, M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
9. [9] Telvekar, V.N.; Kundaikar, H.S. GPR40 carboxylic acid receptor family and diabetes: a new drug target. Curr. Drug Targets, 2008 10, 899-910.
10. [10] Chalmers, D.T.; Behan, D.P. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Discov., 2002, 8, 599-608.
11. [11] Brown, A. J.; Jupe, S.; Briscoe, C. P. A family of fatty acid binding receptors. DNA Cell. Biol., 2005, 24, 54-61.
12. [12] Briscoe, C.P.; Tadayyon, M.; Andrews, J.L.; Benson, W.G.; Chambers, J.K.; Eilert, M.M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R. Jr.; Shabon, U.; Spinage, L.D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. The Orphan G Proteincoupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids. J. Biol. Chem., 2003, 278, 11303-11311.
13. [13] Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature, 2003, 422, 173-176.
14. [14] Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun., 2003, 301, 406-410.
15. [15] Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.Y.; Lannoy, V.; Decobecq, M.E.; Brezillon, S.; Dupriez, V.; Vassart, G.; Van Damme, J.; Parmentier, M.; Detheux, M. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem., 2003, 278, 25481-25489.
16. [16] Nilsson, N.E.; Kotarsy, K.; Owman, C.; Olde, B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun., 2003, 303, 1047-1052.
17. [17] Burant, C.F.; Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes. Diabetes Care, 2013, 36, S175-S179.
18. [18] Zhang Y, Xu M, Zhang S. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse beta-cell line NIT-1. J. Mol. Endocrinol., 2007, 38, 651-661.
19. [19] Alquier T, Peyot ML, Latour MG. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes, 2009, 58, 2607-2615.
20. [20] Latour MG, Alquier T, Oseid E. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes, 2007, 56, 1087-1094.
21. [21] Nagasumi K, Esaki R, Iwachidow K. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes, 2009, 58, 1067-1076.
22. [22] Feng, X.T.; Leng, J.; Xie, Z.; Li, S.L.; Zhao, W.; Tang, Q.L. GPR40: A therapeutic target for mediating insulin secretion (Review). Intl. J. Mol. Med., 2012, 30, 1261-1266.
23. [23] Ferdaoussi M, Bergeron V, Zarrouki B. G protein-coupled receptor (GPR) 40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia, 2012, 55, 2682-2692.
24. [24] Tomita, T.; Masuzaki, H.; Iwakura, H.; Fujikura, J.; Noguchi, M.; Tanaka, T.; Ebihara, K.; Kawamura, J.; Komoto, I.; Kawaguchi, Y.; Fujimoto, K.; Doi, R.; Shimada, Y.; Hosoda, K.; Imamura, M.; Nakao, K. Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion. Diabetologia, 2006, 49, 962-968.
25. [25] Stein, D.T.; Stevenson, B.E.; Chester, M.W.; Basit, M.; Daniels, M. B.; Turley, S.D.; Mcgarry, J.D. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest., 1997, 100, 398-403.
26. [26] Dobbins, R.L.; Chester, M.W.; Daniels, M.B.; Mcgarry, J.D.; Stein, D.T. Circulating fatty acids are essential for efficient glucosestimulated insulin secretion after prolonged fasting in humans. Diabetes, 1998, 47, 1613-1618.
27. [27] Dobbins, R.L.; Chester, M.W.; Stevenson, B.E.; Daniels, M.B.; Stein, D.T.; Mcgarry, J.D. The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. J. Clin. Invest., 1998, 101, 2370-2376.
28. [28] Gravena, C.; Mathias, P.C.; Ashcroft, S.J. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J. Endocrinol., 2002, 173, 73-80.
29. [29] Steneberg, P.; Rubins, N.; Bartoov-Shifman, R.; Walker, M.D.; Edlund, H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab., 2005, 1, 245-258.
30. [30] Shapiro, H.; Shachar, S.; Sekler, I.; Herschfinkel, M.; Walker, M.D. Role of GPR40 in fatty acid action on the β cell line INS-1E. Biochem. Biophys. Res.Commun., 2005, 335, 97-104.
31. [31] Miyazaki, J.; Araki, K.; Yamato, E.; Ikegami, H.; Asano, T.; Shibasaki, Y.; Oka, Y.; Yamamura, K.Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology, 1990, 127, 126-132.
32. [32] Newgard, C.B.; McGarry, J. D. Metabolic coupling factors in pancreatic beta-cell signal transduction. Annu. Rev. Biochem., 1995, 64, 689-719.
33. [33] Steneberg, R.; Rubins, N.; Bartoov-Shifman, R.; Walker, M.D.; Edlund, H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab., 2005, 1, 245-258.
34. [34] Brownlie, R.; Mayers, R.M.; Pierce, J.A.; Marley, A.E.; Smith, D.M. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: Investigations using GPR40-knockout mice. Biochem. Soc. Trans., 2008, 36, 950-954.
35. [35] Latour, M.G.; Alquier, T.; Oseid, E.; Tremblay, C.; Jetton, T.L.; Luo, J.; Lin, D.C.H.; Poitout, V. GPR40 is necessary but notsufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes, 2007, 56, 1087-1094.
36. [36] Kebede, M.; Alquier, T.; Latour, M. G.; Semache, M.; Tremblay, C.; Poitout, V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes, 2008, 57, 2432-2437.
37. [37] Tan, C.P.; Feng, Y.; Zhou, Y.P.; Eiermann, G.J.; Petrov, A.; Zhou, C.Y.; Lin, S.N.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T.E.; Einstein, M.; Kumar, S.; Berger, J.P.; Mills, S.G.; Thornberry, N. A.; Yang, L.H.; Howard, A.D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes, 2008, 57, 2211-2219.
38. [38] Nagasumi, K.; Esaki, R.; Iwachidow, K.; Yasuhara, Y.; Ogi, K.; Tanaka, H.; Nakata, M.; Yano, T.; Shimakawa, K.; Taketomi, S.; Takeuchi, K.; Odaka, H.; Kaisho, Y. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes, 2009, 58, 1067-1076.
39. [39] Lan, H.; Hoos, L.M.; Liu, L.; Tetzloffl, G.; Hu, W.W.; Abbondanzo, S.J.; Vassileva, G.; Gustafson, E.L.; Hedrick, J.A.; Davis, H.R Lack of FFAR1/GPR40 does not protect mice from high-fat dietinduced metabolic disease. Diabetes, 2008, 57, 2999-3006.
40. [40] Alquier, T.; Peyot, M.L.; Latour, M.G.; Kebede, M.; Sorensen, C.M.; Gesta, S.; Kahn, C.R.; Smith, R.D.; Jetton, T.L.; Metz, T.O.; Prentki, M.; Poitout, V. Deletion of GPR40 impairs glucoseinduced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes, 2009, 58, 2607-2615.
41. [41] Rayasam, G.V.; Tulasi, V.K.; Davis, J.A.; Bansal, V.S. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin. Ther. Targets, 2007, 11, 661-671.
42. [42] Rhodes, C.J. Type 2 diabetes-a matter of beta-cell life and death? Science, 2005, 307, 380-384.
43. [43] Donath, M.Y.; Halban, P.A. Decreased beta-cell mass in diabetes: Significance, mechanisms and therapeutic implications. Diabetologia, 2004, 47, 581-589.
44. [44] Stoddart, L.A.; Smith, N.J.; Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev., 2008, 60, 405-417.
45. [45] Wellendorph, P.; Johansen, L.D.; Brauner-Osborne, H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol. Pharmacol., 2009, 76, 453-465.
46. [46] Briscoe, C. P.; Peat, A. J.; McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; McCoy, D. C.; Kenakin, T. P.; Andrews, J. L.; Ammala, C.; Fornwald, J. A.; Ignar, D. M.; Jenkinson, S. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol., 2006, 148, 619-628.
47. [47] Bharate, S.B.; Nemmani, V.S.K.; Vishwakarma, R.A. Progress in the discovery and development of small-molecule modulators of Gprotein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin. Ther. Patents, 2009, 19(2), 237-264.
48. [48] Akerman, M.; Houze, J.; Daniel, C.H.; Liu, J.; Luo, J.; Medina, J. C.; Qiu, W.; Reagan, J.F.; Sharma, R.; Shuttleworth, S.J.; Sun, Y.; Zhang, J.; Zhu, L. World Patent WO2005/086661 A2, 2005.
49. [49] Woo, J.; Cui, S.; Walker, S.D.; Faul, M.M. Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation. Tetrahedron, 2010, 66, 4730-4737.
50. [50] Morrison, H.; Jona, J.; Walker, S.D.; J. Woo, J.; Li, L.; Fang, J.; Development of a suitable salt form for a GPR40 receptor agonist. Org. Process Res. Dev., 2011, 15, 104-111.
51. [51] Garrido, D.M.; Corbett, D.F.; Dwornik, K.A.; Goetz, A.S.; Littleton, T.R.; McKeown, S.C.; Mills, W.Y.; Smalley, T.L.; Briscoe, C.P.; Peat, A.J. Synthesis and activity of small molecule GPR40 agonists. Bioorg. Med. Chem. Lett., 2006, 16, 1840-1845.
52. [52] McKeown, S.C.; Corbett, D.F.; Goetz, A.S.; Littleton, T.R.; Bigham, E.; Briscoe, C.P.; Peat, A.J.; Watson, S.P.; Hickey, D.M.B. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg. Med. Chem. Lett., 2007, 17, 1584-1589.
53. [53] Doshi, L.S.; Brahma, M.K.; Sayyed, S.G.; Dixit, A.V.; Chandak, P.G.; Pamidiboina, V.; Motiwala, H.F.; Sharma, S.D.; Nemmani, K.V.S. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Metabol. Clin. Experiment., 2009, 58, 333-343.
54. [54] Tikhonova I.G.; Sum C.S.; Neuman S.; Thomas C.J.; Raaka B.M.; Costanzi S.; and Gershengorn M.C. Bidirectional, iterative approach to the structural delineation of the functional “Chemoprint” in GPR40 for agonist recognition. J. Med. Chem., 2007, 50, 2981-2989.
55. [55] Tikhonova, I.G.; Sum, C.S.; Neumann, S.; Engel, S.; Raaka, B.M.; Costanzi, S.; Gershengorn, M.C. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J. Med. Chem., 2008, 51, 625-633.
56. [56] Lu, S.Y.; Jiang, Y.J.; Lv, J.; Wu, T.X.; Yu, Q.S.; Zhu, W.L. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions. J. Mol. Graph. Model., 2010, 28, 766-774.
57. [57] Song, F.; Lu, S.; Gunnet, J.; Xu, J. Z.; Wines, P.; Proost, J.; Liang, Y.; Baumann, C.; Lenhard, J.; Murray, W.V.; Demarest, K.T.; Kuo, G.H. Synthesis and biological evaluation of 3-Aryl-3-(4-phenoxy)-propionic acid as a novel series of g protein-coupled receptor 40 agonists. J. Med. Chem., 2007, 50, 2807-2817.
58. [58] Akerman, M.; Brown, S.; Houze, J.B.; Liu, J.; Zhihua, M.A.; Medina, J.C.; Qiu, W.; Schmott, M.J.; Wang, Y.; Zhu, L. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propionic acids useful for treating metabolic disorders. World Patent WO2007033002, March 22, 2007.
59. [59] Yasuma, T.; Negoro, N.; Takashima, H. Cyclopropane carboxylic acid compound. World Patent WO2007/013689 A1, Feb. 01, 2007.
60. [60] Defossa, E.; Goerlitzer, J.; Klabunde, T.; Drosou, V.; Stengelin, S.; Haschke, G.; Herling, A.; Bartoschek, S.; 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments. World Patent WO2007/131620 A2, Nov. 22, 2007.
61. [61] Defossa, E.; Follmann, M.; Klabunde, T.; Drosou, V.; Hessler, G.; Stengelin, S.; Haschke, G.; Herling, A.; Bartoschek, S. Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments. World Patent WO 2007/131622 A1, Nov. 22, 2007.
62. [62] Sharma, R.; Akerman, M.; Cardozo, M.; Li, A.R; Liu, J.; Liu, J.; Ma, Z.; Medina, J.; Schmitt, M.J.; Sun, Y.; Wang, Y.; Wang, Z.; Zhu, Z. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders. World Patent WO2007106469 A2, Sept. 20, 2007.
63. [63] Ge, M.; He, J.; Lau, F.W.; Liang, G.; Lin, S.; Liu, W.; Walsh, S.; Yang, L. Antidiabetic bicyclic compounds. World Patent, WO2007/ 136572 A2, Nov. 29, 2007.
64. [64] Owman, C.; Olde, B.; Rome, D.; Sterner, O. Therapeutic modulators of GPR40. World Patent, WO2007/049050 A2, May 03, 2007.
65. [65] Negoro, K.; Iwasaki, F.; Ohnuki, K.; Kurosaki, T.; Yonetoku, Y.; Asai, N.; Yoshida, S.; Soga, T. Oxadiazolidinedione compound. World Patent WO2007123225, Nov. 01, 2007.
66. [66] Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A.D.; Drewke, C.; Ullrich, S.; Kassack, M.U.; Kostenis, E.; Ulven, T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type ii diabetes. J. Med. Chem., 2008, 51, 7061-7064.
67. [67] Bharate, S.B.; Rodge, A.; Joshi, R.K.; Kaur, J.; Srinivasan, S.; Kumar, S.S.; Almeida, A.K.; Balachandran, S.; Balakrishnan, A.; Vishwakarma, R.A. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg. Med. Chem. Lett., 2008, 18, 6357-6361.
68. [68] Brown, S.P.; Dransfield, P.J.; Fu, Z.; Houze, J.; Jiao, X.Y.; Kohn, T.J.; Pattaropong, V.; Vimolratana, M.; Schitt, M.J.; Substituted biphenyl GPR40 modulators. U.S. Patent 7,572,934 B2, Aug. 11, 2009.
69. [69] Brown, S.P.; Cao, Q.; Dransfield, P.J.; Du, X.; Houze, J.; Jiao, X.Y.; Kohn, T.J.; Lai, S.; Li, A.R.; Lin, D.; Luo, J.; Medina, J.C. Substituted biphenyl GPR40 modulators. World Patent WO2009/048572 A1, April 16, 2009.
70. [70] Kotarsky, K.; Nilsson, N.E.; Olde, B.; Owman, C. Progress in methodology. Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. Pharmacol. Toxicol., 2003, 93, 249-258.
71. [71] Zhou, C.; Tang, C.; Chang, E.; Ge, M.; Lin, S.; Cline, E.; Tan, C.P.; Feng, Y.; Zhou, Y.P.; Eiermann, G. J.; Petrov, A.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J.; Howard, A.D.; Thornberry, N.; Mills, S.G.; Yang, L.; Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonist. Bioorg. Med. Chem. Lett., 2010, 20, 1298-1301.
72. [72] Brown, S.P.; Dransfield, P.; Houze, J.B.; Liu, J.; Liu, J.; Ma, Z.; Medina, J.C.; Pattaropong, V.; Schmitt, M.J.; Sharma, R.; Wang, Y. Benzo-fused compounds for use in treating metabolic disorders. US patent, 7,687,526 B2, Mar. 30, 2010.
73. [73] Christiansen, E.; Due-Hansen, M.E.; Urban, C.; Merten, N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S.S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R.K. Kristiansen, K.; Ullrich, S.; Kostenis, E.; Kassack, M.U.; Ulven, T. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. ACS Med. Chem. Lett., 2010, 1, 345-349.
74. [74] Brown, S.P.; Dransfield, P.; Du, X.; Fu, Z.; Houze, J.B.; Jiao, X.Y.; Lai, S.; Li, A.R.; Liu, J.; Ma, Z.; Medina, J.C.; Pattaropong, V.; Shen, W.; Vimolratana, M.; Wang, Y.; Wang, Z.; Yu, M.; Zhu, L. Spirocyclic GPR40 modulators. World Patent, WO2010/045258 A2, Apr. 22, 2010.
75. [75] Brown, S.P.; Dransfield, P.; Du, X.; Fu, Z.; Houze, J.B.; Jiao, X.Y.; Lai, S.; Li, A.R.; Liu, J.; Ma, Z.; Medina, J.C.; Pattaropong, V.; Shen, W.; Vimolratana, M.; Wang, Y.; Wang, Z.; Yu, M.; Zhu, L. Spirocyclic GPR40 modulators. US patent, US 2011/0190330 A1, Aug. 4, 2011.
76. [76] Beck, H.; Dransfield, P.J.; Fu, Z.; Houze, J.B.; Jiao, X.Y.; Kohn, T.J.; Lai, S.; Liu, J.; Liu, J.; Ma, Z.; Medina, J.C.; Schmitt, M.J.; Sharma, R.; Shen, W.; Vimolratana, M.; Wang, Y.; Wang, Z. Heterocyclic GPR40 modulators. US Patent, 8,003,648 B2, Aug. 23, 2011.
77. [77] Brown, S.P.; Cao, Q.; Dransfield, P.J.; Du, X.; Fu, Z.; Houze, J.; Jiao, X.Y.; Kim, Y.J.; Kohn, T.J.; Lai, S.; Li, A.R.; Lin, D.; Liu, J.; Luo, J.; Medina, J.C.; Reagan, J.D.; Pattaropong, V.; Schwarz, M.; Shen, W.; Su, Y.; Swaminath, G.; Vimolratana, M.; Wang, Y.; Xiong, Y.; Yang, L.; Yu, M.; Zhang, J.; Zhu, L. Substituted biphenyl GPR40 modulators. U.S. Patent 8,030,354 B2, Oct. 4, 2011.
78. [78] Keil, S.; Defossa, E.; Dietrich, V.; Stengelin, S.; Herling, A.; Haschke, G.; Klabunde, T. Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as GPR40 Receptor modulators. World Patent WO 2011/161030 A1, Dec. 29, 2011.
79. [79] Joisen, H.B.; Clader, J.W.; Greenlee, W.J.; Mayer, M.J.; Herr, R.J.; Davis, J.L.; Deng, K.; Hsia, M.; Wan, S. Bridged and fused heterocyclic antidiabetic compounds. US Patent, US 2011/0312995 A1, Dec. 22, 2011.
80. [80] Joisen, H.B.; Clader, J.W.; Stamford, A.; Greenlee, W.J.; Mayer, M.J.; Davis, J.L.; Hsia, M.; Wan, S. Pentafluorosulpholane-containing antidiabetic compounds. US Patent, US 2011/0313008 A1, Dec. 22, 2011.
81. [81] Walsh, S.P.; Severino, A.; Zhou, C.; He, J.; Liang, G.B.; Tan, C. P.; Cao, J.; Eiermann, G. J.; Xu, L.; Salituro, G.; Howard, A. D.; Mills, S.G.; Yang, L. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists. Bioorg. Med. Chem. Lett., 2011, 21, 3390-3394.
82. [82] Sasaki, S.; Kitamura, S.; Negoro, N.; Suzuki, M.; Tsujihata, Y.; Suzuki, N.; Santou, T.; Kanzaki, N.; Harada, M.; Tanaka, Y.; Kobayashi, M.; Tada, N.; Funami, M.; Tanaka, T.; Yamamoto, Y.; Fukatsu, K.; Yasuma, T.; Momose, Y. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J. Med. Chem., 2011, 54, 1365-1378.
83. [83] Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Miyazaki, T.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett., 2010, 1, 290-294.
84. [84] Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Tsujihata, Y.; Ito, R.; Suzuki, M.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Morohashi, A.; Nonaka, M.; Matsunaga, S.; Yasuma, T.; Momose, Y.; Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic acids: Discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J. Med. Chem., 2012, 55, 3960-3974.
85. [85] Araki, T; Hirayama, M; Hiroi, S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes. Metab., 2012, 14, 271-278.
86. [86] Kaku, K.; Araki, T.; Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care, 2013, 36, 245-250.
87. [87] Rao, R.; Arumugam, N.; Ansari, M.; Gudla, C.; Pachiyappan, S.; Ramalingam, M.; George, J.; Arul, G.F.; Bommegowda, Y.; Angupillai, S.K.; kottamalai, R.; Jidugu, P.; Rao, S.D. Agonists of GPR40. World Patent WO2012/011125 A1, Jan 26, 2012.
88. [88] Defossa, E.; Keil, S.; Dietrich, V.; Stengelin, S.; Herling, A.; Haschke, G.; Klabunde, T.; Fischer, H.J. (2-aryloxy-acetylamino)-phenyl propionic acid derivatives, methods for producing same and use thereof as pharmaceuticals. World Patent WO2012/004269 A1, Jan. 12, 2012.
89. [89] Mikami, S.; Kitamura, S.; Negoro, N.; Sasaki, S.; Suzuki, M.; Tsujihata, Y.; Miyazaki, T.; Ito, R.; Suzuki, N.; Miyazaki, J.; Santou, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Yasuma, T.; Momose, Y. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G proteincoupled receptor 40 agonists for the treatment of type 2 diabetes. J. Med. Chem., 2012, 55, 3756-3776.
90. [90] Negoro, K.; Ohnuki, K.; Yonetoku, Y.; Kuramoto, K.; Urano, Y.; Watanabe, H. Carboxylic acid compound. US patent, US 2012/ 0035196 A1, Feb. 9, 2012.
91. [91] Davis, J.L.; Mayer, M.J.; Davis, Joisen H.B. Phthalazine containing antidiabetic compounds. US Patent, US 2012/0004234 A1, Jan. 5, 2012.
92. [92] Hernandez, A.S.; Ellsworth, B.A.; Ewing, W.R.; Chen, B. Dihydropyrazole GPR40 Modulators, WO 2014/078608 Al. May 22, 2014.
93. [93] Abdel-Magid, A.F. Modulators of GPR40 as treatment for diabetes. ACS Med. Chem. Lett., 2014, 5, 954-955.
94. [94] Takano, R., Yoshida, M.; Inoue, M.; Honda, T.; Nakashima, R.; Matsumoto, K.; Yano, Ogata T.; Watanabe, N.; Hirouchi, M.; Yoneyama, T.; Ito, S.; Toda, N.T.; Discovery of DS-1558: A potent and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett., 2015, 6, 266-270.
95. [95] Hansen, S.V.F.; Christiansen, E.; Urban, C.; Hudson, B.D.; Stocker, C.J.; Due-Hansen, M.E.; Wargent, E.T.; Shimpukade, B.; Almeida, R.; Ejsing, C.S.; Cawthorne, M.A.; Kassack, M.U.; Milligan, G.; Ulven, T. Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area, and robust in vivo efficacy. J. Med. Chem., 2016, 59, 2841-2846.
96. Christiansen, E.; Hudson, B.D.; Hansen, A.H.; Milligan, G.; Ulven, T. Development and characterization of a potent free fatty acid receptor 1 (FFA1) Fluorescent Tracer. DOI: 10.1021/acs.jmedchem. 6b00202.
97. [97] Humphries, P.S.; Benbow, J.W.; Bonin, P.D.; Boyer, D.; Doran, S.D.; Frisbie, R.K.; Piotrowski, D.W.; Balan, G.; Bechle, B.M.; Conn, E.L.; Dirico, K.J.; Oliver, R. M.; Soeller, W.C.; Southers, J.A.; Yang, X. Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 2400-2403.
98. [98] Hu, H.; He, L.Y.; Gong, Z.; Li, N.; Lu, Y.N.; Zhai, Q.W.; Liu, H.; Jiang, H.L.; Zhu, W.L., Wang, H.Y. A novel class of antagonists for the FFAs receptor GPR40. Biochem. Biophys. Res. Commun., 2009, 390(3), 557-563.
99. [99] DC260126, a small molecule antagonist GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed. Pharmacother., 2010, 64(9), 647-651.